Published On: Sun, Oct 27th, 2013

Alcobra Raises $33 Million In Secondary Nasdaq Offering

The ADHD treatment developer raised $27 million in its IPO in May.




Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD) raised a gross $33 million in its secondary offering on Thursday. The company issued two million shares at $16.50 per share. The underwriters, Stifel Nicolaus, Aegis Capital Corp., JMP Securities have a 30-day option to buy additional 300, 000 sharesAlcobra will use the proceeds for the development of its proprietary drug, MG01CI (Metadoxine extended-release), for the treatment of ADHD and Fragile X Syndrome, a factor in autism.

Alcobra raised $27 million in its IPO in May.

Alcobra’s share price closed at $17.01 on Friday, giving a market cap of $189 million, after falling 0.5% during the session.


Published by 

Read more about: , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems